CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $155.37M, lower than 95% of all stocks globally
- FinancialsHigh structural barrier to entry
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
The statements on file don't all cover the same year: income statement FY2025, balance sheet FY2024, cash-flow statement FY2024. Each figure below is labelled with the year it comes from.
Financials view
Market Capitalization
115.04MGBP155.37M · vs all stocks (USD)
Revenue (TTM)
955.18KGBP1.29M · vs all stocks (USD)
Profit Margin
0.00%Beta
-0.1550xvs all stocks
52-Week Change
-89.77%vs all stocks
Market Capitalization
115.04MGBP155.37M · vs all stocks (USD)
Enterprise Value
4.35MGBP5.87M · vs all stocks (USD)
Price to Sales (TTM)
1.20xEnterprise to Revenue
4.55xEnterprise to EBITDA
-1.49xProfit Margin
0.00%Operating Margin
-139.26%Revenue (TTM)
955.18KGBP1.29M · vs all stocks (USD)
Revenue per Share (TTM)
0.0190GBPUpdated Jul 27, 2026Quarterly Revenue Growth
412.60%Gross Profit (TTM)
-615.50KGBP-831.25K · vs all stocks (USD)
EBITDA (TTM)
-2.92MGBP-3.94M · vs all stocks (USD)
Net Income (TTM)
-3.20MGBP-4.32M · vs all stocks (USD)
Operating Cash Flow (TTM)
-1.92MGBP-2.60M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
0.00GBPvs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Jul 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%EPS (Basic)
-0.0065GBPFY2025 · Mar 31, 2025EPS (Diluted)
-0.0065GBPFY2025 · Mar 31, 2025Basic Shares Outstanding
506.29MSharesFY2025 · Mar 31, 2025Diluted Shares Outstanding
506.29MSharesFY2025 · Mar 31, 2025Operating Cash Flow
-5.39MGBPFY2024 · Mar 31, 2024Free Cash Flow
-5.39MGBPFY2024 · Mar 31, 2024Cash & Cash Equivalents (End of Period)
1.32MGBPFY2024 · Mar 31, 2024Starting Profit (CF Statement)
-3.37MGBPFY2024 · Mar 31, 2024Stock-based Compensation
0.00GBPFY2024 · Mar 31, 2024Other Non-cash Items
256.27KGBPFY2024 · Mar 31, 2024Change in Accounts Receivable (CF)
-2.21MGBPFY2024 · Mar 31, 2024Change in Other Assets/Liabilities
-63.18KGBPFY2024 · Mar 31, 2024Capital Expenditures
0.00GBPFY2024 · Mar 31, 2024Net Intangibles (CF)
0.00GBPFY2024 · Mar 31, 2024Net Investing Cash Flow
0.00GBPFY2024 · Mar 31, 2024Long-term Debt Issuance
0.00GBPFY2024 · Mar 31, 2024Long-term Debt Payments
-19.29KGBPFY2024 · Mar 31, 2024Other Financing Charges
11.37KGBPFY2024 · Mar 31, 2024Net Financing Cash Flow
2.03MGBPFY2024 · Mar 31, 2024Shares Outstanding
506.29MSharesUpdated Jul 27, 2026Float Shares
37.75MSharesUpdated Jul 27, 2026% Held by Insiders
30.68%vs all stocks
% Held by Institutions
0.01%vs all stocks
Total Cash (MRQ)
37.08KGBP50.07K · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0010GBPUpdated Jul 27, 2026Total Debt (MRQ)
3.24MGBP4.37M · vs all stocks (USD)
Current Ratio (MRQ)
0.3910xBook Value per Share (MRQ)
-0.0440GBPUpdated Jul 27, 2026Total Assets
5.27MGBP7.11M · vs all stocks (USD)
Total Current Assets
3.92MGBPFY2024 · Mar 31, 2024Total Liabilities
2.69MGBPFY2024 · Mar 31, 2024Total Non-current Assets
1.34MGBPFY2024 · Mar 31, 2024Total Non-current Liabilities
1.50MGBPFY2024 · Mar 31, 2024Total Current Liabilities
1.19MGBPFY2024 · Mar 31, 2024Cash
1.32MGBPFY2024 · Mar 31, 2024Cash & Cash Equivalents
1.32MGBPFY2024 · Mar 31, 2024Accounts Receivable
1.37MGBPFY2024 · Mar 31, 2024Inventory
139.84KGBPFY2024 · Mar 31, 2024Accounts Payable
658.14KGBPFY2024 · Mar 31, 2024Short-term Debt
303.41KGBPFY2024 · Mar 31, 2024Long-term Debt
1.50MGBPFY2024 · Mar 31, 2024Common Stock (Book)
4.95MGBPFY2024 · Mar 31, 2024Retained Earnings
-22.28MGBPFY2024 · Mar 31, 2024Total Shareholders' Equity
2.57MGBP3.47M · vs all stocks (USD)
52-Week Low
2.00GBXUpdated Jul 27, 202652-Week High
30.00GBXUpdated Jul 27, 202652-Week Change
-89.77%vs all stocks
Beta
-0.1550xvs all stocks
50-Day MA
2.78GBXUpdated Jul 27, 2026200-Day MA
5.89GBXUpdated Jul 27, 2026Avg 10-Day Volume
58.69KSharesUpdated Jul 27, 2026Avg 30-Day Volume
102.51KSharesUpdated Jul 27, 2026Diluted EPS (TTM)
-0.0600GBPUpdated Jul 27, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.62
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $155.37M, lower than 95% of all stocks globallySignificant
Market cap (USD): 155,370,238.267Global P5: 269,387,740.27
Revenue is $1.29M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,290,003.297Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
S Biomedics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
EKF Diagnostics Holdings plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
HLB Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Yungjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Graphy Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sensorion SA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Mycenax Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Enlivex Therapeutics Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Journey Medical Corp
Tier 1ProductionApproval-Gated PipelineRule
Alector Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Neuromeka Co., Ltd.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Geoharbour Construction Group Co. Ltd.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated